Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles
Massachusetts Institute of Technology · Institute of Chemical Engineering · +3 more institutions
Abstract
Cisplatin is used to treat a variety of tumors, but dose limiting toxicities or intrinsic and acquired resistance limit its application in many types of cancer including prostate. We report a unique strategy to deliver cisplatin to prostate cancer cells by constructing Pt(IV)-encapsulated prostate-specific membrane antigen (PSMA) targeted nanoparticles (NPs) of poly(D,L-lactic-co-glycolic acid) (PLGA)-poly(ethylene glycol) (PEG)-functionalized controlled release polymers. By using PLGA-b-PEG nanoparticles with PSMA targeting aptamers (Apt) on the surface as a vehicle for the platinum(IV) compound c,t,c-[Pt(NH(3))(2)(O(2)CCH(2)CH(2)CH(2)CH(2)CH(3))(2)Cl(2)] (1), a lethal dose of cisplatin was delivered…
Citation impact
- FWCI
- 21.62
- Percentile
- 100%
- References
- 46
Authors
5- SDShanta DharCorresponding
Massachusetts Institute of Technology
- FGFrank Gu
Institute of Chemical Engineering, Massachusetts Institute of Technology
- RLRóbert Langer
Institute of Chemical Engineering, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology
- OCOmid C. Farokhzad
Brigham and Women's Hospital, Harvard University, Massachusetts Institute of Technology
- SJStephen J. Lippard
Koch Institute for Integrative Cancer Research At MIT
Topics & keywords
- LNCaP
- PLGA
- Cisplatin
- Aptamer
- Chemistry
- Prostate cancer
- Nanocarriers
- Drug delivery
- Good health and well-being